Sparton — Q1 FY2013 Earnings Presentation
12 slides from Sparton's earnings presentation, Nov 7, 2012
Slide 1: Fiscal 2013 First Quarter Financial Results Conference Call
Exhibit 99.2 Fiscal 2013 First Quarter Financial Results Conference Call November 7, 2012
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements herein constitute forward-looking statements within the meaning of the Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended. When used herein, words such as “believe,” “expect,” “anticipate,” “project,” “plan,” “estimate,” “w
Slide 3: Today's Agenda
Today’s Agenda st • 1 Quarter Highlights • Fiscal 2013 First Quarter Results • Segmented Operating Results • Liquidity & Capital Resources • Pending Acquisition of Onyx • Outlook • Q&A 3
Slide 4: 1st Quarter Highlights
st 1 Quarter Highlights • 14 new business programs with estimated future annualized revenue of $13.4 million. • Quarter end sales backlog of approximately $156.1 million, up 6% from the previous quarter and up 7% increase over a year ago. • Medical business continued sales growth of 2.2% with a gros
Slide 5: Consolidated Financial Results
Consolidated Financial Results Fiscal 2013 First Quarter (Reported) Quarter ended Sept 30, YoY 2012 2011 Variance Net Sales $ 49,020 $ 51,833 $ (2,813) Gross Profit 7,213 8,344 (1,131) 14.7% 16.1% Selling and Administrative Expense 5,472 5,411 61 Internal R&D Expense 305 398 (93) Amortization of int
Slide 6: Sales & Gross Margin Results: Medical
Sales & Gross Margin Results Medical SALES 3 Months Ended Sept 30, SEGMENT 2012 % of Total 2011 % Change Medical $ 28,059 57% $ 27,460 2% Complex Systems 12,347 25% 12,560 -2% DSS 13,206 27% 15,287 -14% Eliminations (4,592) -9% (3,474) 32% Totals $ 49,020 100% $ 51,833 -5% GROSS MARGIN 3 Months Ende
Slide 7: Sales & Gross Margin Results: Complex Systems
Sales & Gross Margin Results Complex Systems SALES 3 Months Ended Sept 30, SEGMENT 2012 % of Total 2011 % Change Medical $ 28,059 57% $ 27,460 2% Complex Systems 12,347 25% 12,560 -2% DSS 13,206 27% 15,287 -14% Eliminations (4,592) -9% (3,474) 32% Totals $ 49,020 100% $ 51,833 -5% GROSS MARGIN 3 Mon
Slide 8: Sales & Gross Margin Results: Defense & Security Systems
Sales & Gross Margin Results Defense & Security Systems SALES 3 Months Ended Sept 30, SEGMENT 2012 % of Total 2011 % Change Medical $ 28,059 57% $ 27,460 2% Complex Systems 12,347 25% 12,560 -2% DSS 13,206 27% 15,287 -14% Eliminations (4,592) -9% (3,474) 32% Totals $ 49,020 100% $ 51,833 -5% GROSS M
Slide 9: Liquidity & Capital Resources
Liquidity & Capital Resources Cash Availability ($ in '000) Sep-11 Dec-11 Mar-12 Jun-12 Sep-12 Cash and equivalents 26,984 30,610 26,682 46,950 43,096 LOC Availability 17,533 17,290 16,469 16,277 16,012 Total 44,517 47,900 43,151 63,227 59,108 Debt ($ in '000) Sep-11 Dec-11 Mar-12 Jun-12 Sep-12 Cred
Slide 10: Pending Acquisition of Onyx
Pending Acquisition of Onyx • $43.25 million purchase price, all-cash transaction. • $50 million of revenue at 18% gross profit (TTM as of June 30, 2012). • Onyx primarily manufactures devices for OEM and emerging technology companies in the Medical and Industrial markets. • Strategic implications…
Slide 11: Fiscal 2013 Outlook
Fiscal 2013 Outlook • Implementation of the strategic growth plan – Continue to gain traction on a nationally focused direct selling effort – Further leverage Viet Nam as a low cost country alternative and in-region provider – Maintain our level of investment in internal research & development to co
Slide 12: Q&A
CA) (9) Sparton Q&A 12